|
Study ID (First author, year)
|
Total test results available
|
Type of IGRA test and TST (thresholds)
|
Number of people with positive results
|
Number of people with negative results
|
People with test positive results who progressed to TB (n)
|
People with test negative results who progressed to TB (n)
|
|---|
|
Children
|
|
Diel, 2011 [11]
|
104
|
QFT-GIT
|
21
|
83
|
6
|
0
|
|
TST (≥5 mm)
|
40
|
64
|
6
|
0
|
|
TST (≥10 mm)
|
40
|
64
|
4
|
2
|
|
Mahomed, 2011 [13]
|
5244
|
QFT-GIT
|
2669
|
2575
|
39
|
13
|
|
TST (≥5 mm)
|
2894
|
2350
|
40
|
12
|
|
Metin Timur, 2014 [14]
|
69
|
QFT-GIT
|
0
|
69
|
0
|
0
|
|
TST (≥15 mm)
|
69
|
0
|
0
|
0
|
|
Noorbakhsh, 2011 [15]
|
59
|
QFT-G
|
18
|
41
|
10
|
0
|
|
58
|
TST (≥10 mm)
|
8
|
50
|
3
|
7
|
|
Song, 2014 [16]
|
2966
|
QFT-GIT
|
317
|
2649
|
11
|
12
|
|
2982
|
TST (≥10 mm)
|
663
|
2319
|
13
|
10
|
|
TST (≥15 mm)
|
231
|
2751
|
13
|
10
|
|
Immunocompromised
|
|
Elzi, 2011 [12]
|
43
|
T-SPOT.TB
|
25
|
18
|
25
|
18
|
|
44
|
TST (≥5 mm)
|
22
|
22
|
22
|
22
|
|
Kim, 2011 [17]
|
265
|
T-SPOT.TB
|
89
|
176
|
4
|
0
|
|
288
|
TST (≥5 mm)
|
26
|
262
|
1
|
3
|
|
Kim, 2015a [18]
|
282
|
QFT-GIT
|
7
|
275
|
0
|
1
|
|
282
|
TST (≥5 mm)
|
12
|
270
|
0
|
1
|
|
Lee, 2009 [19]
|
30
|
QFT-G
|
12
|
18
|
1
|
0
|
|
T-SPOT.TB
|
15
|
17
|
0
|
2
|
|
TST (≥10 mm)
|
20
|
12
|
1
|
1
|
|
Lee, 2014 [22]
|
159
|
QFT-GIT
|
26
|
133
|
3
|
2
|
|
169
|
TST (≥10 mm)
|
19
|
150
|
0
|
5
|
|
TST (≥15 mm)
|
12
|
157
|
0
|
5
|
|
Lee, 2015b [23]
|
342
|
QFT-GIT
|
103
|
239
|
N/A
|
4
|
|
239
|
TST (≥10 mm)
|
60
|
179
|
2
|
2
|
|
Milman, 2011 [20]
|
41
|
QFT-G
|
0
|
41
|
0
|
0
|
|
12
|
TST (≥10 mm)
|
0
|
12
|
0
|
0
|
|
Moon, 2013 [21]
|
210
|
QFT-GIT
|
40
|
170
|
1
|
1
|
|
244
|
TST (≥5 mm)
|
39
|
205
|
0
|
2
|
|
Sester, 2014 [24]
|
1238
|
QFT-GIT
|
159
|
1079
|
3
|
5
|
|
1217
|
T-SPOT.TB
|
193
|
1024
|
4
|
6
|
|
1282
|
TST (≥5 mm)
|
149
|
1133
|
4
|
7
|
|
Sherkat, 2014 [25]
|
44
|
T-SPOT.TB
|
6
|
38
|
1
|
0
|
|
TST (≥10 mm)
|
8
|
36
|
1
|
0
|
|
Recent arrivals from countries with a high incidence of TB
|
|
Harstad, 2010 [26]
|
815
|
QFT-GIT
|
238
|
577
|
8
|
1
|
| |
TST (≥6 mm)
|
415
|
395
|
8
|
1
|
|
813
|
TST (≥15 mm)
|
121
|
692
|
3
|
6
|
|
Kik, 2010 [27]
|
327
|
QFT-GIT
|
178
|
149
|
5
|
3
|
|
299
|
T-SPOT.TB
|
181
|
118
|
6
|
2
|
|
339
|
TST (≥10 mm)
|
288
|
51
|
9
|
0
|
|
322
|
TST (≥15 mm)
|
184
|
138
|
7
|
1
|
-
N/A not applicable, QFT-G quantiferon gold, QFT-GIT quantiferon gold-in-tube, TB tuberculosis, TST tuberculin skin test, n number
-
aOne unique study but three sub-groups received testing (TST alone, QFT-GIT alone and TST and QFT-GIT simultaneously)
-
bPeople with a positive result on QFT-GIT received TB preventative treatment
